78917-44-9

Basic information

• Product Name: ETHYL 3-BENZOFURAN-2-YL-3-OXO-PROPIONATE
• Synonyms: ETHYL 3-(BENZO[B]FURAN-2-YL)-3-OXOPROPANOATE;ETHYL 3-BENZOFURAN-2-YL-3-OXO-PROPIONATE;ETHYL 3-(1-BENZOFURAN-2-YL)-3-OXOPROPANOATE;Ethyl 3-(benzofuran-2-yl)-3-oxopropanoate
• CAS NO: 78917-44-9
• Molecular Formula: C₁₃H₁₂O₄
• Molecular Weight: 232.23
• Mol File: 78917-44-9.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 329.8 °C at 760 mmHg
• Flash Point: 153.3 °C
• Appearance: /
• Density: 1.216 g/cm³
• Vapor Pressure: 0.000173mmHg at 25°C
• Refractive Index: 1.564
• Storage Temp.: 2-8°C
• PKA: 9.29±0.46(Predicted)
• CAS DataBase Reference: ETHYL 3-BENZOFURAN-2-YL-3-OXO-PROPIONATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL 3-BENZOFURAN-2-YL-3-OXO-PROPIONATE(78917-44-9)
• EPA Substance Registry System: ETHYL 3-BENZOFURAN-2-YL-3-OXO-PROPIONATE(78917-44-9)

Safety Data

• Hazardous Substances Data: 78917-44-9(Hazardous Substances Data)

Usage

General Description

Ethyl 3-benzofuran-2-yl-3-oxo-propionate is a chemical compound commonly used in synthetic organic chemistry. Its importance lies in its function as an intermediatory compound, meaning it serves as an important transitional product in the chemical reaction sequence designed to synthesize various end products. The exact properties of this chemical may vary, but it belongs to the family of benzofurans, which are most often used in the manufacturing of pharmaceutical agents and fine chemicals due to their biological activity. ETHYL 3-BENZOFURAN-2-YL-3-OXO-PROPIONATE incorporates both the functionality of esters and ketones, which enhances its reactivity and versatility in synthesis processes. It can contribute to the formation of a wide variety of chemical structures and is therefore of great importance in chemical research and industrial manufacturing processes.

InChI:InChI=1/C13H12O4/c1-2-16-13(15)8-10(14)12-7-9-5-3-4-6-11(9)17-12/h3-7H,2,8H2,1H3

Upstream product

• 41717-28-6 2-benzofuroyl chloride 
• 141-97-9 ethyl acetoacetate 
• 638-07-3 ethyl (2-chloroaceto)acetate 
• 90-02-8 salicylaldehyde 
• 141-78-6 ethyl acetate 
• 64-17-5 ethanol 
• 1404448-96-9 5-(benzofuran-2-carbonyl)-2,2-dimethyl-1,3-dioxane-4,6-dione 
• 1646-26-0 1-(benzo[b]furan-2-yl)ethanone 
• 105-58-8 Diethyl carbonate 
• 496-41-3 Benzofuran-2-carboxylic acid 
• 3199-61-9 ethyl coumarilate 
• 1646-27-1 methyl benzofuran-2-carboxylate 

Downstream Products

• 36754-60-6 2-(chloromethyl)-1-benzofuran 

Relevant articles and documents

Catalytic, Cascade Ring-Opening Benzannulations of 2,3-Dihydrofuran O,O- and N,O-Acetals

An Al(OTf)3-catalyzed intramolecular cascade ring-opening benzannulation of 2,3-dihydrofuran O,O- and N,O-acetals is described. The cascade sequence involves the dihydrofuran ring-opening by acetal hydrolysis, an intramolecular Prins-type cyclization, and aromatization to generate an array of benzo-fused (hetero)aromatic systems in up to 95 % yield. This method represents the first example of dihydrofuran acetal usage in benzannulation reactions. The approach provides excellent regiocontrol based on the choice of alkenes used to form the requisite dihydrofuran acetals.

HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK

Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.

Compounds for treatment of cardiac arrhythmia synthesis, and methods of use

The subject invention pertains to novel compounds, and compositions comprising the compounds, for the treatment of cardiac arrhythmias. The subject invention further concerns a method of making the novel compounds. The novel compounds are rapidly metabolized analogs of amiodarone, having the distinct and advantageous characteristic of being metabolized to a less lipophilic compound. The new compounds can have particular utility for treating life-threatening ventricular tachyarrhythmias, especially in patients with congestive heart failure (CHF). The product can also provide effective management for ventricular arrhythmias and supraventricular arrhythmias, including atrial fibrillation and re-entrant tachyarrhythmias involving accessory pathways.